What’s the current market cap for ProAssurance stock?

ProAssurance (PRA) has a market cap of $1.3bn as of June 17, 2026.

What is the P/E ratio for ProAssurance stock?

The price to earnings (P/E) ratio for ProAssurance (PRA) stock is 19.55 as of June 17, 2026.

Does ProAssurance stock pay dividends?

No, ProAssurance (PRA) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next ProAssurance dividend payment date?

ProAssurance (PRA) stock does not pay dividends to its shareholders.

What is the beta indicator for ProAssurance?

ProAssurance (PRA) has a beta rating of 0.04. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy ProAssurance stock | $PRA Share Price

13:30

21:10

04:45

12:25

20:00

About ProAssurance

ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in four segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.

Ticker

$PRA

Sector

Finance

Primary listing

NYSE

Employees

972

Headquarters

Birmingham, United States

Website

www.proassurance.com

ProAssurance Metrics

BasicAdvanced

$1.3bn

19.55

$1.26

0.04

What the Analysts think about ProAssurance

Analyst ratings (Buy, Hold, Sell) for ProAssurance stock.

Bulls say / Bears say

ProAssurance posted a net income of $8.5 million in Q1 2026 versus a $5.8 million loss a year earlier, marking a strong return to profitability (Nasdaq).

Non-GAAP operating income increased 86.7% to $12.7 million year-over-year in Q1 2026, accompanied by a 2.3-point improvement in the consolidated non-GAAP combined ratio to 109.9%, reflecting underwriting performance progress (Nasdaq).

Specialty P&C renewal premiums rose 6% in Q1, part of an 80% cumulative rate increase since 2018, demonstrating sustained pricing power in the medical professional liability market (Nasdaq).

Despite improvement, the consolidated non-GAAP combined ratio stood at 109.9% in Q1, indicating continued underwriting losses above the breakeven threshold (Nasdaq).

The company recorded net investment losses of $3.4 million in Q1 2026, underscoring potential volatility and risk in its investment portfolio (Nasdaq).

The pending merger with The Doctors Company remains subject to final regulatory approvals in California and Pennsylvania, creating uncertainty around the transaction’s timing and completion (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

ProAssurance Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ProAssurance Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRA

Capital at risk

Market open

Upcoming events

No upcoming events